In the case of a woman with metastatic non–small cell lung cancer, answer question of what you would do in terms of treatment and management, as well as questions about your practice.
Share your perspective on a patient case with related polling questions about your practice and opinions on treatment in non–small cell lung cancer (NSCLC). All oncology practices see different patients and have their own protocols for treatment. In this case, chemoimmunotherapy regimens are considered from the phase 3 POSEIDON (NCT03164616), EMPOWER-Lung 3 (NCT03409614), KEYNOTE-407 (NCT02775435), and CheckMate 9LA(NCT03215706) trials.
CASE SUMMARY
What percentage of patients do you treat with advanced stage or metastatic squamous NSCLC?
CASE CONTINUED
Should patients with metastatic NSCLC without actionable driver mutations and PD-L1 greater than 50% receive chemoimmunotherapy?
Which combination therapy would you use for this patient?
CASE CONTINUED
Have you ever used nivolumab/ipilimumab plus 2 cycles of chemotherapy in practice?
CASE CONTINUED
For this patient with grade 3 diarrhea, your next step is to:
CASE CONTINUED
CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma
October 24th 2024During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment.
Read More
Bispecific Antibodies and ADCs Deliver a Futuristic Horizon Across Lung Cancer Settings
October 23rd 2024Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced non-small cell lung cancer.
Read More
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More